ArticleMolecular pharmaceutics2014
Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: in vitro and in vivo evaluation.
Article in Molecular pharmaceutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 114 citations in OpenAlex.
- Exploring Novel Strategies for Improving the Bioavailability of Docetaxel.AAPS PharmSciTech · 2026Review
- Drug Release, Entrapment Efficacy, and Drug Loading Capacity of Taxanes Loaded Solid Lipid Nanoparticles (SLNs).Anti-cancer agents in medicinal chemistry · 2026Review
- Innovative approaches in breast cancer therapy: repurposing nanocarriers for enhanced outcomes.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Inhalable Nano Formulation of Cabazitaxel: A Comparative Study with Intravenous Route.Macromolecular bioscience · 2025Article
- Solid lipid nanoparticles in pancreatic cancer treatment.BJC reports · 2025Review
- Solid Lipid Nanoparticles as an Innovative Lipidic Drug Delivery System.Pharmaceutical nanotechnology · 2025Review
- Ciprofloxacin Derivative-Loaded Nanoparticles Synergize with Paclitaxel Against Type II Human Endometrial Cancer.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Article
- Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer.Molecules (Basel, Switzerland) · 2024Review
- Several Applications of Solid Lipid Nanoparticles in Drug Delivery.Current molecular medicine · 2024Review
- Cubic nanoparticles as potential carriers for a natural anticancer drug: development, in vitro and in vivo characterization.Drug delivery and translational research · 2023Article
- Novel Meta-iodobenzylguanidine and Etoposide Complex: Physicochemical Characterization and Mathematical Modeling of Anticancer Activity.AAPS PharmSciTech · 2023Article
- Chitosan-Coated SLN: A Potential System for Ocular Delivery of Metronidazole.Pharmaceutics · 2023Article
- Nanostructured Lipid Carrier Co-Loaded with Docetaxel and Magnetic Nanoparticles: Physicochemical Characterization and In Vitro Evaluation.Pharmaceutics · 2023Article
- Advances in Lung Cancer Treatment Using Nanomedicines.ACS omega · 2023Review
- Lipid-based oral formulation in capsules to improve the delivery of poorly water-soluble drugs.Frontiers in drug delivery · 2023Review
- Docetaxel Loaded in Copaiba Oil-Nanostructured Lipid Carriers as a Promising DDS for Breast Cancer Treatment.Molecules (Basel, Switzerland) · 2022Article
- Cisplatin-Loaded Tobacco Mosaic Virus for Ovarian Cancer Treatment.Biomacromolecules · 2022Article
- Biopolymeric Prodrug Systems as Potential Antineoplastic Therapy.Pharmaceutics · 2022Review
- The MEK 1/2 inhibitor PD98059 exhibits synergistic anti-endometrial cancer activity with paclitaxel in vitro and enhanced tissue distribution in vivo when formulated into PAMAM-coated PLGA-PEG nanoparticles.Drug delivery and translational research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Docetaxel (DCX) is a second generation taxane. It is approved by the U.S. Food and Drug Administration for the treatment of various types of cancer, including breast, non-small cell lung, and head and neck cancers. However, side effects, including those related to Tween 80, an excipient in current DCX formulations, can be severe. In the present study, we developed a novel solid lipid nanoparticle (SLN) composition of DCX. Trimyristin was selected from a list of high melting point triglycerides as the core lipid component of the SLNs, based on the rate at which the DCX was released from the SLNs and the stability of the SLNs. The trimyristin-based, PEGylated DCX-incorporated SLNs (DCX-SLNs) showed significantly higher cytotoxicity against various human and murine cancer cells in culture, as compared to DCX solubilized in a Tween 80/ethanol solution. Moreover, in a mouse model with pre-established tumors, the new DCX-SLNs were significantly more effective than DCX solubilized in a Tween 80/ethanol solution in inhibiting tumor growth without toxicity, likely because the DCX-SLNs increased the concentration of DCX in tumor tissues, but decreased the levels of DCX in major organs such as liver, spleen, heart, lung, and kidney. DCX-incorporated SLNs prepared with one or more high-melting point triglycerides may represent an improved DCX formulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.